| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ALS9; HEL168; RNASE4; RNASE5 |
| WB Predicted band size | 17 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ANG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PKD1抗体的3篇代表性文献示例(文献信息为示例性质，可能非真实存在)：
---
1. **文献名称**: *"Development and Validation of a Monoclonal Antibody Targeting the C-Terminal Region of Polycystin-1 (PKD1)"*
**作者**: Smith, J.R. et al.
**摘要**: 该研究开发了一种针对PKD1蛋白C末端的高特异性单克隆抗体，并通过免疫印迹和免疫荧光验证其在人肾组织中的反应性，证实其在ADPKD患者中多囊蛋白-1表达异常的检测能力。
2. **文献名称**: *"Epitope Mapping of PKD1 Antibodies Reveals Functional Domains of Polycystin-1"*
**作者**: Garcia-Gonzalez, M.A. et al.
**摘要**: 通过表位定位技术解析了多种商业PKD1抗体的结合区域，发现部分抗体靶向多囊蛋白-1的细胞外结构域，为研究其与纤毛信号通路的相互作用提供了工具。
3. **文献名称**: *"A Novel PKD1 Antibody for Detecting Splicing Variants in Polycystic Kidney Disease Models"*
**作者**: Li, X. et al.
**摘要**: 报道了一种新型抗体，可识别PKD1的特定剪接变体，并在小鼠和细胞模型中验证了其在疾病早期诊断及分子机制研究中的应用潜力。
---
如需真实文献，建议通过PubMed或Google Scholar以关键词“PKD1 antibody”、“polycystin-1 antibody”检索近年研究。
The PKD1 antibody is a crucial tool in studying autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder primarily caused by mutations in the *PKD1* gene. This gene encodes polycystin-1. a large transmembrane protein involved in cell-cell and cell-matrix interactions, calcium signaling, and renal tubular development. Dysfunctional polycystin-1 disrupts these processes, leading to cyst formation in kidneys and other organs.
PKD1 antibodies are designed to detect polycystin-1 in research applications, such as Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate protein expression patterns, subcellular localization, and interactions in normal vs. diseased tissues. Due to the complexity of the *PKD1* gene (46 exons) and the protein’s size (~460 kDa), developing specific antibodies is challenging. Many commercial PKD1 antibodies target epitopes in the extracellular N-terminal region or intracellular C-terminal domain. However, variability in specificity and sensitivity across clones necessitates careful validation using knockout controls or siRNA-based approaches.
These antibodies have advanced ADPKD research by enabling mechanistic studies on cystogenesis, drug screening, and biomarker discovery. They also hold diagnostic potential in assessing polycystin-1 levels in clinical samples. Despite their utility, limitations persist, including cross-reactivity with homologous proteins like polycystin-2 (PKD2) or non-specific binding, underscoring the need for rigorous experimental optimization.
×
